Fulgent Genetics, Inc. (FLGT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong financial performance with improved gross margins, reduced operating expenses, and a positive adjusted EBITDA. Revenue guidance has been raised, and there is optimism about future growth due to new product launches and market expansion. While management avoided specific guidance on some aspects, the overall sentiment is positive due to strategic advancements and financial health improvements. The Q&A session provided reassurance on collection issues and highlighted growth drivers, supporting a positive outlook for stock price movement.
Key Financial Performance
Laboratory Services Revenue $84 million, up $7.2 million or 16.4% year-over-year. The increase is attributed to growth in Precision Diagnostics and Biopharma, despite a decline in Anatomic Pathology.
Precision Diagnostics Revenue Up $7.2 million or 16.4% year-over-year. Growth driven by enhanced offerings like whole genome sequencing and ultrarapid whole genome sequencing services.
Biopharma Revenue Up $3.3 million or 83.4% year-over-year. Growth attributed to increased demand and expanded services.
Anatomic Pathology Revenue Up $1.8 million or 7.2% year-over-year. Growth despite a sequential decline due to timing of collections.
Gross Margin (Non-GAAP) 44.3%, improved year-over-year due to streamlined operations and enhanced efficiency from investments in scaling and centralizing lab operations.
Operating Expenses (Non-GAAP) $40.7 million, decreased from the previous quarter due to reduced advertising, marketing expenses, and improved collections from Precision Diagnostics.
GAAP Loss $6.6 million, improved from $19 million in the prior quarter. Improvement due to reduced operating expenses and absence of a prior one-time noncash charge.
Adjusted EBITDA $0.7 million, compared to a loss of $3 million in Q2 2025. Improvement driven by increased revenue and operational efficiency.
Cash Position $787.7 million, increased due to strong operating cash flows, partially offset by capital expenditures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Enhanced Whole Genome Sequencing: Introduced an enhanced version incorporating RNA analysis to improve diagnostic yield. Launched ultrarapid whole genome sequencing service providing preliminary reports within 48 hours and comprehensive reports within 5 days, targeting NICU applications.
Beacon Carrier Screening Service: Expanded panel to 1,000 genes with the launch of Beacon K, enhancing detection of rare genetic conditions. Maintains high analytical detection rates and fast turnaround time of 8.8 days.
EZOPath IMS: Developed proprietary image management system for digital pathology, enabling AI integration, collaboration, and efficient case management.
NICU Market: Targeting neonatal intensive care units with ultrarapid genome sequencing, which can improve medical management for up to 87% of babies and reduce healthcare costs by up to $15,000 per child.
AI and Digital Pathology: Investments in AI and digital pathology solutions have improved efficiency and precision in laboratory services.
Revenue Growth: Laboratory services revenue reached $84 million, with significant year-over-year growth in Precision Diagnostics (16.4%) and Biopharma (83.4%).
Cost Efficiency: Streamlined operations and centralized lab operations have improved gross margins year-over-year.
Therapeutic Development Pipeline: Progressing well with FID-007 in Phase II trials showing promising efficacy and safety for head and neck cancer. FID-022 Phase I trial initiated for solid tumors.
Revenue Guidance: Raised full-year 2025 revenue outlook to $325 million, representing 15% year-over-year growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges risks related to forward-looking statements and regulatory filings, which may impact actual results. Additionally, delays in tax refunds due to government shutdowns could affect cash flow.
Market and Competitive Pressures: The company faces competitive pressures in genetic screening and laboratory services, requiring continuous innovation and investment to maintain market position.
Operational Challenges: Operational challenges include the need for efficient scaling and centralization of lab operations, as well as managing high daily case throughput in pathology services.
Economic Uncertainties: Economic uncertainties, such as potential delays in tax refunds and the impact of minimal COVID-19 testing revenue, could affect financial performance.
Strategic Execution Risks: The company must successfully execute its strategic objectives, including the development and commercialization of therapeutic candidates like FID-007 and FID-022, while managing R&D and marketing expenses.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Therapeutic Development Pipeline: FID-007 is progressing through a Phase II clinical trial with full data readout expected in 2026. FID-022 has begun a Phase I trial, with the second dose level commencing this month.
Laboratory Services Revenue: Annual revenue guidance for 2025 has been raised to $325 million, representing a 15% year-over-year growth.
Gross Margins: Non-GAAP gross margins for the full year 2025 are expected to exceed 40%.
Operating Margins: Non-GAAP operating margins are expected to improve from minus 15% to minus 10% for 2025.
Earnings Per Share (EPS): Non-GAAP EPS guidance for 2025 has been revised to a positive $0.30 per share, up from a loss of $0.35 per share.
Cash Position: The company anticipates ending 2025 with approximately $800 million in cash, cash equivalents, and investments, assuming receipt of $106 million in tax refunds.
Product Launches: Launch of ultrarapid whole genome sequencing service and Beacon K carrier screening service, expected to drive growth in laboratory services.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Repurchase Program: In the third quarter, we did not repurchase any shares under our stock repurchase program. Since the inception of the stock repurchase program in March 2022, a total of approximately $110.4 million has been spent with approximately $139.6 million remaining available for future repurchase of our common stock.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the ultimate operating margin target for the lab segment?
A:Paul Kim mentioned that the gross margins for the quarter were high at 44.3%, slightly higher than Q2, due to efficiencies, automation, and streamlined policies. Ming Hsieh added that AI technology and digitalization of pathology services are expected to improve margins further, but no specific numbers were provided.
Q:Will there be a catch-up in Q4 for the timing issues in AP collections?
A:Brandon Perthuis explained that the timing issue was related to collections in the quarter, which reduced recognized revenue. However, collections have already begun to improve, and this trend is expected to continue in the next few quarters.
Q:How will the new Precision Diagnostics products support growth, and what is the outlook for 2026?
A:Brandon Perthuis highlighted the launch of a rapid whole genome sequencing test targeted at NICU patients and the expansion of the Beacon panel to 1,000 genes. These products are expected to drive growth, with the rapid genome test offering faster results and a favorable margin profile. The Beacon panel's quick turnaround time and expanded gene coverage provide a competitive advantage. The company is confident in achieving double-digit growth forward but did not provide specific 2026 projections.
Q:Do physicians prefer bundled tests like KNOVA and Beacon, and how are they reimbursed?
A:Brandon Perthuis stated that NIPT and carrier screening are often ordered together in the OB/GYN and MFM markets. KNOVA and Beacon are separate tests with independent billing, not bundled together. The strategy is to sell them together clinically.
Q:What is the update on reimbursement for expanded carrier screening and microdeletions?
A:Brandon Perthuis noted that while an ACOG update on expanded carrier screening is delayed, payers are proactively reimbursing based on demonstrated clinical value. Grassroots efforts and payer collaborations are helping expand access, and a new ACOG guideline would further benefit the industry.
Q:What are the key milestones and costs for FID-107 moving from Phase II to Phase III?
A:Ming Hsieh stated that enrollment for Phase II is expected to finish by the end of 2025, with data presented at ASCO in May 2026. Phase III is estimated to involve 300 patients and cost around $60 million. Paul Kim added that 2025 cash spend for therapeutics development is anticipated to be $25 million, with current spending being efficient.
Q:What caused the timing issue in Anatomic Pathology collections, and is it resolved?
A:Brandon Perthuis explained that the issue was due to a change in billing software, which has since been implemented successfully. Collections are improving, and the issue was specific to Anatomic Pathology.
Q:What drove the strong performance in Pharma Services this quarter?
A:Brandon Perthuis attributed the strength to expanded capabilities beyond NGS, allowing the company to address a larger market and respond to more RFPs. While the business remains lumpy, the pipeline and feedback from biopharma partners are strong.
Q:What are the growth contributions in Precision Diagnostics, and how are Beacon and KNOVA performing?
A:Brandon Perthuis stated that Beacon continues to grow and is a significant contributor to revenue, especially in fertility markets. KNOVA is not yet a meaningful contributor but is expected to grow as it penetrates the OB/GYN market. Exomes, genomes, and oncology tests are also performing well.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers for the ultimate operating margin target for the lab segment, citing the use of new technologies and digitalization efforts. Additionally, no specific revenue projections for 2026 were given despite confidence in double-digit growth.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI module
AI pathology
AI technology
AI tool
Anatomic Pathology
Congress
EZOPath
IMS
Ming
NICU
Phase
ability
arm milligram
call
carrier screening
case
date
dose level
efficacy
genome
health care
image
integration
investment AI
launch
meter arm
milligram arm
milligram meter
panel gene
party
pathology slide
remainder
service investment
solution
system
FLGT Transcript
Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
Unknown5-1
The earnings call reveals several negative factors: a significant decline in revenue, reduced gross margins, increased losses, and a major customer's transition impacting sales. Despite management's confidence in margin recovery and ongoing product development, the financial performance remains weak. The Q&A section showed uncertainty regarding future growth and a lack of clarity on strategic impacts, such as the CMS CRUSH initiative. While share repurchases and cash reserves are positive, they don't offset the broader negative sentiment. Given these factors, a negative stock price movement is likely in the short term.
Fulgent Genetics, Inc. (FLGT) Q4 2025 Earnings Call Transcript
Unknown2-27
The earnings call presents a mixed picture: strong revenue growth in several segments and improved margins are positive, but significant customer loss and increased expenses are concerning. The optimistic guidance and strategic initiatives in AI and genomics are promising, yet the conservative revenue loss estimate and expected cash burn are potential negatives. The Q&A reveals management's confidence in future growth but lacks clarity on cost synergies and AI strategy. Given these factors, the stock price reaction is likely to be neutral over the next two weeks.
Fulgent Genetics, Inc. (FLGT) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-11
Fulgent Genetics, Inc. (FLGT) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call indicates strong financial performance with improved gross margins, reduced operating expenses, and a positive adjusted EBITDA. Revenue guidance has been raised, and there is optimism about future growth due to new product launches and market expansion. While management avoided specific guidance on some aspects, the overall sentiment is positive due to strategic advancements and financial health improvements. The Q&A session provided reassurance on collection issues and highlighted growth drivers, supporting a positive outlook for stock price movement.
FLGT Slides
FLGT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
